INTRODUCTION
============

Eating disorders aggregate in family,[@B1] and the variance in heredity lies between 33% and 84% in twin studies.[@B2] Using endophenotypic markers may have great potential for finding the candidate genes, as they are generally less complex than their associated phenotype and, thus, may be more readily linked to a specific genetic locus.[@B3] It has been suggested that the cognitive behavioral inflexibility observed in patients with eating disorders is linked to their set-shifting problem.[@B4] The set-shifting ability is considered as a candidate endophenotype of anorexia nervosa (AN),[@B5] because pairs of sisters one of whom has AN as well as women with AN, tend to have delayed set-shifting.[@B6] Whereas there is accumulating evidence for impaired set-shifting ability in AN, much remains unknown with respect to bulimia nervosa (BN).[@B7] The catechol-O-methyltransferase (*COMT*) gene is one of the candidate genes for impaired cognitive flexibility. The *COMT* Val158Met functional polymorphism appears to selectively impact prefrontal dopamine regulation and this gene has been shown to predict performance on prefrontal executive cognition and working memory tasks in healthy individuals.[@B8]

In the present study, we hypothesized that individuals with BN as well as AN would show impaired set-shifting ability. An extensive review of the previous literature guided our choice of the Trail Making Test (TMT)[@B9] as the measure to use for the set-shifting ability, as it is the most commonly employed set-shifting measure with the acceptable and consistent effect size.[@B7] We also attempted to investigate whether their set-shifting ability is affected by the *COMT* Val158Met genotype. To the best of our knowledge, this is the first study to examine the possible association between endophenotypes and liable genes in eating disorders.

METHODS
=======

A total of 102 women, comprising 40 patients with AN and 28 patients with BN, as well as 34 healthy controls, participated in this study. The diagnosis of lifetime AN or BN was made using the Eating Disorders Examination Questionnaire Version (EDE-Q)[@B10] on the basis of the hierarchical model of diagnosis used in a genetic study.[@B11] Neuropsychological tests were applied to all participants and their blood samples were collected for the *COMT* Val158Met genotyping. The exclusion criteria for all participants were a history of neurologic illness, brain injury, substance-abuse disorders, or psychosis in the past. Only the use of selective serotonin reuptake inhibitors (SSRIs) was permitted within 2 weeks before the neuropsychological test. Nineteen (48%) of AN and fifteen (54%) of BN were taking SSRIs at the time of the study. The Korean version of the Wechsler Adult Intelligent Scale was administered to match the groups in terms of their general intelligence.[@B12] The patients underwent an interview for measuring their symptoms of eating disorders by using the Korean version of the 12th edition of the EDE.[@B13] Their comorbid clinical symptoms were measured by the Korean versions of the Beck Depression Inventory (BDI),[@B14] the Spielberger State and Trait Anxiety Inventory,[@B15] and the Maudsley Obsessive Compulsive Inventory,[@B16] respectively. The participants completed various computerized neuropsychological tests spanning the cognitive domains of the TMT Part B for set-shifting ability, the Visual Span Test (VST; Corsi block tapping test)[@B17] for visual/working memory, the TMT Part A[@B9] for attention, and the Finger Tapping Test (FTT)[@B18] for motor function. A meta-analysis revealed no evidence of publication bias for the TMT Part B[@B7] and, therefore, the uncorrected data is presented in this study. According to Korean normative data, the test/retest reliability coefficients of the computerized tests were acceptable.[@B19],[@B20] Deoxyribonucleic acid (DNA) was extracted from blood leukocytes by using a commercial DNA extraction kit (ABI, Foster City, CA, USA). Genotyping of the *COMT* Val158Met variant was carried out with a polymerase chain reaction (PCR)-based restriction fragment length polymorphism analysis by using the primers 5\'-CTCATCACCA TCGAGATCAA-3\' and 5\'-CCAGGTCTGAAACGGGTCA-3\'. The PCR products digested with *Nla*III were electrophoresed to distinguish between the Val and Met alleles. This study was approved by the Institutional Review Board of Seoul Paik Hospital in Seoul, Korea. Written informed consent was obtained from all of the participants.

Group differences in the neuropsychological tests were tested in a one-way analysis of covariance with the years of education included as a covariate, since the AN group had a shorter educational years than the other groups (AN: 12.70±3.38 years, BN: 13.57±2.20 years, controls: 14.65±1.87 years; F=4.99, df=2/99, p=0.009). For the set-shifting ability, a multivariate analysis of variance (MANOVA) in the groups was com-puted by integrating the two scores of the TMT Part B (total errors, time taken). The MANCOVAs were repeated using the general psychiatric measures as covariates to investigate the contribution of general psychiatric symptoms on the performance on the neuropsychological tests. We carried out the subsidiary analysis to test the effect of medication on the performance of the neuropsychological tests with a comparison of the patients in the medicated subgroup with those in the non-medicated subgroup. For effect of the *COMT* genotype on the set-shifting ability, a two way MANOVA for integrating the time taken and total errors of the TMT Part B was computed with the two factors, genotype and group. Two-tailed tests were used and a p-value \<0.05 was considered to be indicative of statistical significance.

RESULTS
=======

The clinical characteristics, the frequency of genotypes for the *COMT* Val158Met, and the performance on the neuropsychological tests of the participants are shown in [Table 1](#T1){ref-type="table"}. Both the AN and BN groups showed significantly poorer performance on the TMT Part A and FTT than the controls, but not on the VST. The MANOVA showed a significant effect of diagnosis on the set-shifting ability with Pillai\'s F=4.48, df=4/196, p=0.002 on the TMT Part B. Depression was slightly associated with the performance on the set-shifting task (F=3.38, df=2/93, p=0.038), but the effect of the group were also significant for the score of BDI as a covariate (F=3.36, df=4/188, p=0.011). There was no evidence that anxiety, obsessive-compulsiveness, or symptoms of eating disorders was associated with the set-shifting ability. In a subsidiary analysis, the results revealed no significant group differences across all neuropsychological tasks in comparisons of the women with eating disorders who were or were not currently receiving antidepressants. We could not find any main effect of the COMT Val158 Met genotype (F=0.54, df=4/184, p=0.703), group (F=2.41, df=4/184, p=0.051), or any interaction effects between the genotype and group (F=0.50, df=8/184, p=0.858) on the performance of the set-shifting ability.

DISCUSSION
==========

In this study, we reported set-shifting impairments were found in patients with AN and BN, respectively. Furthermore, the eating disorders were also linked to deficits in attentional mechanisms and motor skills. This study furthers our understanding of the possibility of set-shifting deficit being used as an endophenotype of BN as well as AN.

These neuropsychological data are consistent with previous evidence of there being an impairment in attention and motor skill in underweight and recovered AN and BN patients, but no differences in the working memory or speed of memory.[@B21] Although the performance on the set-shifting task was related to depression, the set-shifting deficit still remained after controlling for the effect of depression, indicating the deficit is a feature independent of the comorbidities.

In our study, the *COMT* Val158Met genotype was not involved in the impaired set-shifting ability in both AN and BN. Despite this finding, there is no doubt that genetic variants are associated with the endophenotype (viz. set-shifting deficit). It may be more useful to use of the endophenotypic marker for uncovering genetic commonalities across psychiatric disorders than for a single disorder (viz. eating disorder) as set-shifting appears to broadly increase the risk of many forms of psychiatric illness.[@B22]-[@B24] The limitations of the study were to use of the TMT Part B solely as a measure of the set-shifting ability, and the relatively small sample size, which may reduce its power to detect an association. Furthermore, the multiple testings to examine links between the set-shifting deficit and possible genetic markers might increase the probability of type 1 errors.

In conclusion, our findings suggest that impaired set-shifting ability is a common feature for both AN and BN patients and its link to eating disorders were not moderated by the *COMT* Val158Met genotype.
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Data are shown as mean±SD or number (percentage) as appropriate. The differences in the genotype frequencies between the patients (AN, BN) and the healthy controls were evaluated using a χ^2^ test. Analysis by ANCOVA for neuropsychological tasks as covariate of years of education. ^\*^p\<0.05, ^\*\*^p\<0.01 compared on cognitive performance as contrasted with controls. N/A: no normative data given, AN: anorexia nervosa, BN: bulimia nervosa, HC: healthy controls, BMI: Body Mass Index, K-WAIS: Korean-Wechsler Adult Intelligent Scale, BDI: Beck Depression Inventory, STAI: State and Trait Anxiety Inventory, K-MOCI: Korean version of Maudsley Obsessive and Compulsive Inventory, EDE: Eating Disorders Examination Interview
